Stock Analiz

JNJ vs AZN stock comparison

Johnson & Johnson vs. Astrazeneca · data as of November 13, 2026

Johnson & Johnson (JNJ) has a market value of about $687.9B, Astrazeneca (AZN) about $286.0B. Over their latest twelve months Johnson & Johnson had revenue of $99.3B and Astrazeneca $62.4B.

On our five checks Astrazeneca scores higher: 2.8 out of 5 (average) against 2.6 (average).

By area, the stronger company is Astrazeneca on value; Astrazeneca on future growth; Johnson & Johnson on financial health; Johnson & Johnson on shareholder returns.

Astrazeneca is cheaper on earnings (P/E 26.1 vs. 43.4).

Johnson & Johnson leads on 8 of the compared lines and Astrazeneca on 16.

Side by side

JNJAZN
Size and price
Market cap$687.9B$286.0B
Share price$285.75$184.45
Score
Overall score (of 5)2.62.8
Value01
Future growth02
Track record44
Financial health43
Shareholder returns54
Valuation
P/E (TTM)43.426.1
Forward P/E25.116.5
Price / free cash flow33.446.9
Price / sales6.94.6
EV / EBITDA26.714.7
PEG2.911.20
DCF value vs. price−39%−38%
Business
Revenue$99.3B$62.4B
Net income$16.1B$11.0B
Free cash flow$20.6B$6.1B
Net margin16.2%17.7%
Gross margin (5-yr avg.)69.1%76.8%
ROIC (5-yr avg.)16.6%8.4%
Growth
Revenue growth (1 yr)6.0%8.6%
Revenue growth (5 yrs, per year)2.7%17.2%
EPS growth (5 yrs, per year)14.9%21.8%
Balance sheet and payouts
Net cash (cash minus debt)-$27.4B-$26.0B
Dividend yield1.88%1.74%
Shareholder yield2.8%1.9%
Analysts
Upside to average target−2%+13%
Consensus ratingBuyBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: JNJ TTM to September 27, 2026, AZN TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Johnson & Johnson or Astrazeneca?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Astrazeneca scores 2.8 out of 5 and Johnson & Johnson 2.6; the table shows where each one is stronger.

Is Johnson & Johnson cheaper than Astrazeneca?

On trailing earnings, Astrazeneca trades at a P/E of 26.1 and Johnson & Johnson at 43.4, so Astrazeneca is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Johnson & Johnson or Astrazeneca?

Over five years Astrazeneca grew revenue about 17.2% a year and Johnson & Johnson about 2.7% a year.

Which pays a higher dividend?

Johnson & Johnson yields 1.88% and Astrazeneca 1.74%.

Full Johnson & Johnson analysis → Full Astrazeneca analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.